A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.

about

Salivary gland ultrasonography as a predictor of clinical activity in Sjögren's syndrome Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.

P2860

Q38636845-4E098DB6-8BBA-44EF-ABB8-48AE89E51069 Q48341665-B1FC72B6-C42A-4561-9D37-B86383F3519A

P2860

A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.

Item

http://www.wikidata.org/entity/Q38389487

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A phase II investigator-initia ...... in primary Sjögren's syndrome.

@en

type

Item

label

A phase II investigator-initia ...... in primary Sjögren's syndrome.

@en

prefLabel

A phase II investigator-initia ...... in primary Sjögren's syndrome.

@en

P1476

A phase II investigator-initia ...... in primary Sjögren's syndrome.

@en

P2093

Anja Hagemann

http://www.w3.org/2001/XMLSchema#string

Claudia Kedor

http://www.w3.org/2001/XMLSchema#string

Eugen Feist

http://www.w3.org/2001/XMLSchema#string

Jan Zernicke

http://www.w3.org/2001/XMLSchema#string

Johanna Callhoff

http://www.w3.org/2001/XMLSchema#string

Lorena Martinez Gamboa

http://www.w3.org/2001/XMLSchema#string

P2860

Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients.

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

Clinical manifestations and early diagnosis of Sjögren syndrome.

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome.

Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.

Treatment of primary Sjögren syndrome: a systematic review.

Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Chec

Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Asse

Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions.

P304

2203-2210

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10067-016-3360-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gerd-Rüdiger Burmester

P577

2016-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27470087

http://www.w3.org/2001/XMLSchema#string

A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.

about

P2860

P2860

A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698